Free tool
Drug Trial Radar: Rare and genetic disease
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
5
Not yet recruiting, industry sponsors, Rare and genetic disease, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed102
5 trials
Showing 1 to 5, recently updated first.
- A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)Pivotal-lookingNot yet recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07559513 · 18 participants (planned) · Start Feb 2, 2027 · Primary completion Jul 8, 2030
Drug: garetosmab · For: Fibrodysplasia Ossificans Progressiva; FOP
- The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)Pivotal-lookingNot yet recruiting
SanofiSanofi (SNY)
NCT07927140 · 18 participants (planned) · Start Dec 11, 2026 · Primary completion Jan 14, 2030
Drug: Venglustat; Imiglucerase · For: Gaucher's Disease Type III
- Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal DisordersPivotal-lookingNot yet recruiting
Azafaros B.V.Industry
NCT07885917 · 218 participants (planned) · Start Dec 10, 2026 · Primary completion Apr 1, 2030
Drug: AZ-3102 · For: Niemann-Pick Disease Type C; GM2 Gangliosidosis; GM1 Gangliosidosis and 1 more
- Study of Velaglucerase Beta ERT in Children With Gaucher DiseasePivotal-lookingNot yet recruiting
CANbridge Life Sciences Ltd.Industry
NCT07847411 · 10 participants (planned) · Start Sep 16, 2026 · Primary completion Feb 25, 2028
Drug: Velaglucerase beta · For: Gaucher Disease; Gaucher Disease Type 1; Gaucher Disease Type 3
Sites: Shanghai, China
- Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B)Pivotal-lookingNot yet recruiting
Spruce BiosciencesIndustry
NCT07579910 · 14 participants (planned) · Start Dec 2026 · Primary completion Aug 2033
Drug: Tralesinidase alfa (TA) · For: MPS IIIB
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.